Liminatus Pharma, Inc. Warrants

Liminatus Pharma (LIMN) received a delisting notice from Nasdaq on May 20, 2026, after failing to meet minimum market value requirements ($50M MVLS and $15M MVPHS) within the 180-day compliance period. The company intends to appeal the decision before the Nasdaq Hearings Panel by May 27, 2026, which will stay any suspension pending the hearing.

Liminatus Pharma announced a definitive merger agreement with InnocsAI LLC, a biotechnology company specializing in CAR-T and antibody-based oncology therapies. Under the agreement, InnocsAI members will receive 1.6 billion shares of Liminatus common stock at $0.20 per share, valuing the transaction at approximately $320 million. The merger aims ...

Liminatus Pharma (LIMN) shares surged 79.34% to $0.34 in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal brings a clinical-stage oncology portfolio including CAR-T and solid tumor programs. However, the stock has declined 96.95% over the past 12 months and trades near its 52-week low, wi...

Liminatus Pharma (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering of 13.8 million shares and warrants at $0.29 per share, expected to raise approximately $4.0 million in gross proceeds. The offering is expected to close on February 18, 2026, with net proceeds to be used for working capital a...

Liminatus Pharma, a clinical-stage immuno-oncology company, has entered a Memorandum of Understanding with Capital Trust Group for a $30 million equity investment to support its research and development of advanced immunotherapy assets.